Tamanho de recipientes e tempo de formação de mudas no desenvolvimento e produção de maracujazeiro-amarelo

O tamanho de recipientes e o tempo de formação em viveiro são fatores diretamente relacionados com a qualidade das mudas de maracujazeiro, mas é importante verificar se o maior desenvolvimento da muda se reflete no desempenho das plantas adultas a campo. Assim, o objetivo deste trabalho foi avaliar a influência do tamanho de recipientes e do tempo de formação das mudas no desenvolvimento e na produção de maracujazeiro-amarelo. O delineamento experimental utilizado foi de blocos ao acaso, arranjados em esquema fatorial 3 (tamanhos de recipientes) x 3 (períodos de formação das mudas), com quatro repetições e quatro plantas por parcela. Os recipientes avaliados tinham volumes de 400; 800 e 1.200 cm³, e as semeaduras foram realizadas em março, abril e maio. As mudas foram transplantadas para o campo,em setembro, com 180; 150 e 120 dias de formação em viveiro. Foram avaliados a altura das mudas no transplante, a produção total, o número de frutos por planta e a massa dos frutos durante o 1º ciclo de produção. O desenvolvimento vegetativo da parte aérea das mudas é proporcional ao tamanho do recipiente e ao tempo para formação. Semeaduras realizadas no mês de maio, em recipientes de 1.200 cm³, são mais apropriadas por apresentarem produção de frutos maior e/ou igual aos demais tratamentos, em menor período de formação.

Avaliação nutricional, produção e incidência do mal-do-panamá em bananeira 'Prata-Anã' (AAB) adubada com K, no quarto ciclo

O presente trabalho teve como objetivos estimar a dose de K para obter a máxima eficiência física e econômica, estimar o nível crítico foliar de K e relacionar o equilíbrio nutricional da bananeira 'Prata-Anã' com a incidência de plantas com mal-do-panamá no 4º ciclo. O experimento foi realizado em Latossolo Vermelho-Amarelo (LVA), textura média, na região semiárida do norte de Minas Gerais, Brasil. Os tratamentos consistiram nas aplicações de quatro doses de K (0; 400; 800 e 1.200 kg ha-1 ano de K2O). Estes foram distribuídos em blocos ao acaso, com cinco repetições. A adubação com K promoveu aumento na produção da bananeira no 4º ciclo. A máxima eficiência física (31 Mg ha-1) e a econômica (30,5 Mg ha-1) foram obtidas com as aplicações de 969 e 707 kg ha-1 ano-1 de K2O, respectivamente. Os níveis críticos foliares de K obtidos foram 29,5 e 27,1 g kg-1, para a máxima eficiência física e econômica, respectivamente. O aumento das doses de K proporcionou melhor equilíbrio nutricional à bananeira e reduziu a porcentagem de plantas infestadas com o mal-do-panamá.

Estabelecimento de meio de cultura e quantificação da germinação de grãos de pólen de cultivares de marmeleiros

Visando a dar suporte aos trabalhos de melhoramento genético do marmeleiro (Cydoniaoblonga Mill.), voltados para a seleção de cultivares altamente produtivas, aptas a serem cultivadas em regiões subtropicais e produtoras de doces de qualidade superior, objetivou-se ajustar o meio de cultura básico para a germinação de grãos de pólen de diferentes cultivares dessa espécie e quantificar o número de estames, número de grãos de pólen por antera e por flor. O pólen utilizado foi da cultivar Portugal, obtido de anteras provenientes de flores em estádio de balão. Em seguida, com auxílio de um pincel, os grãos de pólen foram espalhados sobre a superfície de placas de Petri, contendo 20 mL de meio de cultura, de acordo com os seguintes experimentos: 1) concentrações de ágar (4; 6; 8 e 10 g L-1) e valores de pH (3,5; 4,5; 5,5 e 6,5); 2) concentrações de sacarose (0; 30; 60 e 90 g L-1); 3) concentrações de nitrato de cálcio (0; 200; 400 e 800 mg L-1); 4) concentrações de ácido bórico (0; 400; 800 e 1.200 mg L-1); e 5) tempo de emissão do tubo polínico (0; 1; 2; 3; 4; 5 e 6 horas após a inoculação), os quais foram montados de forma sequencial. Após, avaliou-se a taxa de germinação dos grãos de pólen das 27 cultivares (Alaranjado, Alongado, Apple, BA29, Bereckzy, Champion, Cheldow, Constantinopla, CTS 207, Dangers, De Patras, De Vranja, Dulot, Fuller, Mendoza INTA 37, Kiakami, Lajeado, Meeck Profilic, Meliforme, Pineapple, Portugal, Provence, Radaelli, Rea's Mamouth, Smyrna, Van Deman e Zuquerineta), além do número de estames, número de grãos de pólen por antera e por flor. Realizando-se as leituras da porcentagem de germinação após cinco horas de incubação, conclui-se que o meio de cultura para a germinação de grãos de pólen do marmeleiro deve ser acrescido de 68 g L-1 de sacarose e 366 mg L-1 de ácido bórico, sendo o pH aferido para 5,8 e o meio solidificado com 10 g L-1 de ágar. Foram constatadas diferenças entre as cultivares quanto à quantidade de grãos de pólen e à capacidade germinativa dos mesmos, que variou de 37,83% a 82,23% entre as cultivares. Os grãos de pólen da cultivar Alaranjado apresentaram maior porcentagem de germinação, além da maior quantidade de grãos de pólen por flor.

Efeito do tratamento de bacelos de videira 'Red Globe' no controle do cancro bacteriano causado por Xanthomonas campestris pv. viticola

A disseminação de Xanthomonas campestris pv. viticola (Xcv), agente do cancro bacteriano da videira, ocorre, dentre outras formas, por meio de mudas e bacelos infectados. Foi estudada a obtenção de material propagativo livre do patógeno, testando a eficiência do tratamento de bacelos com termoterapia, bactericidas e sanitizantes. Os isolados de Xcv foram testados quanto à patogenicidade e realizado o teste de sensibilidade in vitro aos produtos, em diferentes concentrações. A erradicação de Xcv em bacelos de videira foi testada em experimentos com termoterapia (50ºC por 30 e 40 min; 53ºC por 5 e 10 min); bactericidas [oxitetraciclina+sulfato de cobre (150+2.000; 165+2.200; 180+2.400 e 195+2.600 mg L-1 de H2O) e oxitetraciclina (600; 700; 800 e 900 mg L-1)]; e sanitizantes [cloreto de dodecildimetil amônio (600; 1.200; 1.800; 2.400 e 3.000 µL L-1); hipoclorito de sódio (5.000; 10.000; 20.000; 30.000 e 40.000 µL L-1) e cloreto de benzalcônio (125; 167;250; 334 e 500 µL L-1)]. Foram avaliados período de incubação, incidência e severidade da doença. O bactericida oxitetraciclina e os sanitizantes cloreto de dodecildimetil amônio e hipoclorito de sódio proporcionaram os maiores halos de inibição de Xcv in vitro. No entanto, apesar dos diversos tratamentos testados, não foi possível recomendar tratamento termoterápico ou produto que erradicasse Xcv de bacelos infectados. Porém, ficou confirmada a grande importância destes na disseminação do agente do cancro bacteriano da videira.

Propuesta de un plan de desarrollo integral del guanábano (Annona muricata L.) en el estado de Veracruz México

El estado de Veracruz tiene una superficie de 71' 227 km². Cuenta con una zona potencialmente apta para el cultivo del guanábano de 18' 440 ha, (0.21%), una zona medianamente propicia de 3' 645 324 ha (51.30%) y una zona no apropiada de 3' 458 862 ha, (48.44%). Existen 20 municipios productores de guanábano en el estado de Veracruz. Actualmente la demanda por este producto ha permitido su incremento en superficie estimándose en 800 ha, en estos últimos años. Con un rendimiento aproximado de 5.0 ton/ha, por debajo de la media nacional que es de 6.5 ton/ha, esto refleja la poco tecnología empleada en el manejo del cultivo. Lamentablemente el desarrollo de este frutal en Veracruz se ha realizado de una manera desordenada. Todo ello, sin ninguna planeación y sin un estudio sobre un ordenamiento agroecológico a fin de detectar áreas potencialmente aptas para este cultivo. A pesar de toda esta complejidad se ha llegado a considerar como un frutal digno de atención por las posibilidades agroindustriales que representa. En general son tres los principales puntos prioritarios a tomar en cuenta para esta estrategia de desarrollo: Primero las características genéticas del material de propagación. Segundo las condiciones de sanidad de las plantas, principal factor que podría ser limitativo para el desarrollo del guanábano. Tercero la tecnología de producción. Existe desconocimiento en la lámina e intervalo riego, época; dosis y fuente de fertilización; época y tipo de poda. Existe una gran fortaleza en su aprovechamiento integral de este frutal: comercial, industrial, medicinal, farmacéutico, fitotóxico, alimenticio, entre otras propiedades.

Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort

BACKGROUND: Data evaluating the chronological order of appearance of extraintestinal manifestations (EIMs) relative to the time of inflammatory bowel disease (IBD) diagnosis is currently lacking. We aimed to assess the type, frequency, and chronological order of appearance of EIMs in patients with IBD. METHODS: Data from the Swiss Inflammatory Bowel Disease Cohort Study were analyzed. RESULTS: The data on 1249 patients were analyzed (49.8% female, median age: 40 [interquartile range, 30-51 yr], 735 [58.8%] with Crohn's disease, 483 [38.7%] with ulcerative colitis, and 31 [2.5%] with indeterminate colitis). A total of 366 patients presented with EIMs (29.3%). Of those, 63.4% presented with 1, 26.5% with 2, 4.9% with 3, 2.5% with 4, and 2.7% with 5 EIMs during their lifetime. Patients presented with the following diseases as first EIMs: peripheral arthritis 70.0%, aphthous stomatitis 21.6%, axial arthropathy/ankylosing spondylitis 16.4%, uveitis 13.7%, erythema nodosum 12.6%, primary sclerosing cholangitis 6.6%, pyoderma gangrenosum 4.9%, and psoriasis 2.7%. In 25.8% of cases, patients presented with their first EIM before IBD was diagnosed (median time 5 mo before IBD diagnosis: range, 0-25 mo), and in 74.2% of cases, the first EIM manifested itself after IBD diagnosis (median: 92 mo; range, 29-183 mo). CONCLUSIONS: In one quarter of patients with IBD, EIMs appeared before the time of IBD diagnosis. Occurrence of EIMs should prompt physicians to look for potential underlying IBD.

High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis.

We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.

The SwissLipids knowledgebase for lipid biology.

MOTIVATION: Lipids are a large and diverse group of biological molecules with roles in membrane formation, energy storage and signaling. Cellular lipidomes may contain tens of thousands of structures, a staggering degree of complexity whose significance is not yet fully understood. High-throughput mass spectrometry-based platforms provide a means to study this complexity, but the interpretation of lipidomic data and its integration with prior knowledge of lipid biology suffers from a lack of appropriate tools to manage the data and extract knowledge from it. RESULTS: To facilitate the description and exploration of lipidomic data and its integration with prior biological knowledge, we have developed a knowledge resource for lipids and their biology-SwissLipids. SwissLipids provides curated knowledge of lipid structures and metabolism which is used to generate an in silico library of feasible lipid structures. These are arranged in a hierarchical classification that links mass spectrometry analytical outputs to all possible lipid structures, metabolic reactions and enzymes. SwissLipids provides a reference namespace for lipidomic data publication, data exploration and hypothesis generation. The current version of SwissLipids includes over 244 000 known and theoretically possible lipid structures, over 800 proteins, and curated links to published knowledge from over 620 peer-reviewed publications. We are continually updating the SwissLipids hierarchy with new lipid categories and new expert curated knowledge. AVAILABILITY: SwissLipids is freely available at http://www.swisslipids.org/. CONTACT: alan.bridge@isb-sib.ch SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Lappeenrannan teknillisen yliopiston opiskelijoiden yrittäjyyshalukkuus, yrittäjyyssopivuus ja opintomenestys

The aim of this thesis was to clarify willingness and suitability for entrepreneurship among students of Lappeenranta University of Technology (LUT). In addition factors that would explain academic achievement and if there were relationship between academic achievement and willingness or suitability for entrepreneurship were examined. Questionnaires were sent via e-mail to 800 students of LUT in summer 2007. Response percent was 29,6 %. Based on the collected answers factors of entrepreneurial motivation and academic achievement were analyzed using mainly Pearson’s correlation coefficient and factor analysis. In the light of these factors willingness and suitability for entrepreneurship and academic achievement were examined. The results indicated that 36,7 % of the respondents were willing and 11,4 % were suitable for entrepreneurship. The largest share of the willing ones was focused on Department of Mechanical Engineering, whereas the smallest share on Department of Environmental Technology. The largest shares of the suitable ones were on Departments of Mechanical and Electrical Engineering, and the smallest shares on Departments of Environmental, Chemical and Energy Technology. Academic achievement was affected by, among others, exercising and success in high school. Academic achievement and willingness or suitability for entrepreneurship didn’t correlate. Yet, from factors of entrepreneurial motivation internal locus of control correlated positively with academic achievement.

Families in the Shadow of Cancer

The aims of this study were 1) to clarify the factors associated with family functioning in cancer patient’s families with dependant children, 2) to examine children’ mental health when they are exposed to parental cancer, 3) to explore the subjective experience of having cancer during pregnancy, and finally, 4) to describe the implementation of a childcentred family intervention for cancer patients’ families with dependant children in an adult oncology setting. The study groups were collected between May 1st 2002 and April 30th 2004. They consisted of one European group collected from six different countries (N = 381) and two Finnish clinical groups (N = 85 and N = 2). The first Finnish clinical group of 85 cancer patient families with dependant children included a sub-sample of 54 families with children aged 11-17 years. The second Finnish clinical group consisted of two pregnant cancer patients. Additionally, a control group (N = 59) consisting of a sub-sample of 49 families with children aged 11-17 years was used. Quantitative methods (FAD, BDI, YSR, SOC, SF-8) and qualitative methods (observation, interviews, diaries, videotapes) were used exclusively and/or in combination. The results can be summarised as follows: 1) cancer “per se “ did not impair family functioning, children’s mental health, early interaction between ill mothers and their infant, 2) maternal depression or the ill parent’s depression were significantly associated with impairment in family functioning, 3) the individual’s good sense of coherence was associated with improvement in family functioning, and 4) a child-centred family intervention, which aims to give space for elaborating on cancer in the family, validates the sense of coherence and children’s feelings, and promotes open communication was welcomed. It is important to note that in the European study group, the prevalence of depression was 35 % (BDI > 16) among ill mothers, and 28% among healthy mothers, 28% among ill fathers, and 13% among healthy fathers. Early screening and effective treatment of depression in cancer patients and their partners is of paramount importance for the mental health of children and the well-being of the family. Pregnant cancer patients are in need of psychosocial support.

Ability of physicians to diagnose influenza and usefulness of a rapid influenza antigen test in febrile returning travelers: A randomized controlled trial.

BACKGROUND: Fever is a frequent cause of medical consultation among returning travelers. The objectives of this study were to assess whether physicians were able to identify patients with influenza and whether the use of an influenza rapid diagnostic test (iRDT) modified the clinical management of such patients. METHODS: Randomized controlled trial conducted at 2 different Swiss hospitals between December 2008 and November 2012. Inclusion criteria were 1) age ≥18 years, 2) documented fever of ≥38 °C or anamnestic fever + cough or sore throat within the last 4 days, 3) illness occurring within 14 days after returning from a trip abroad, 4) no definitive alternative diagnosis. Physicians were asked to estimate the likelihood of influenza on clinical grounds, and a single nasopharyngeal swab was taken. Thereafter patients were randomized into 2 groups: i) patients with iRDT (BD Directigen A + B) performed on the nasopharyngeal swab, ii) patients receiving usual care. A quantitative PCR to detect influenza was done on all nasopharyngeal swabs after the recruitment period. Clinical management was evaluated on the basis of cost of medical care, number of X-rays requested and prescription of anti-infective drugs. RESULTS: 100 eligible patients were referred to the investigators. 93 patients had a naso-pharyngeal swab for a PCR and 28 (30%) swabs were positive for influenza. The median probability of influenza estimated by the physician was 70% for the PCR positive cases and 30% for the PCR negative cases (p < 0.001). The sensitivity of the iRDT was only 20%, and specificity 100%. Mean medical cost for the patients managed with iRDT and without iRDT were USD 581 (95%CI 454-707) and USD 661 (95%CI 522-800) respectively. 14/60 (23%) of the patients managed with iRDT were prescribed antibiotics versus 13/33 (39%) in the control group (p = 0.15). No patient received antiviral treatment. CONCLUSION: Influenza was a frequent cause of fever among these febrile returning travelers. Based on their clinical assessment, physicians had a higher level of suspicion for influenza in PCR positive cases. The iRDT used in this study showed a disappointingly low sensitivity and can therefore not be recommended for the management of these patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT00821626.

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.

BACKGROUND: The primary analysis of the FLAMINGO study at 48 weeks showed that patients taking dolutegravir once daily had a significantly higher virological response rate than did those taking ritonavir-boosted darunavir once daily, with similar tolerability. We present secondary efficacy and safety results analysed at 96 weeks. METHODS: FLAMINGO was a multicentre, open-label, phase 3b, non-inferiority study of HIV-1-infected treatment-naive adults. Patients were randomly assigned (1:1) to dolutegravir 50 mg or darunavir 800 mg plus ritonavir 100 mg, with investigator-selected combination tenofovir and emtricitabine or combination abacavir and lamivudine background treatment. The main endpoints were plasma HIV-1 RNA less than 50 copies per mL and safety. The non-inferiority margin was -12%. If the lower end of the 95% CI was greater than 0%, then we concluded that dolutegravir was superior to ritonavir-boosted darunavir. This trial is registered with ClinicalTrials.gov, number NCT01449929. FINDINGS: Of 595 patients screened, 488 were randomly assigned and 484 included in the analysis (242 assigned to receive dolutegravir and 242 assigned to receive ritonavir-boosted darunavir). At 96 weeks, 194 (80%) of 242 patients in the dolutegravir group and 164 (68%) of 242 in the ritonavir-boosted darunavir group had HIV-1 RNA less than 50 copies per mL (adjusted difference 12·4, 95% CI 4·7-20·2; p=0·002), with the greatest difference in patients with high viral load at baseline (50/61 [82%] vs 32/61 [52%], homogeneity test p=0·014). Six participants (three since 48 weeks) in the dolutegravir group and 13 (four) in the darunavir plus ritonavir group discontinued because of adverse events. The most common drug-related adverse events were diarrhoea (23/242 [10%] in the dolutegravir group vs 57/242 [24%] in the darunavir plus ritonavir group), nausea (31/242 [13%] vs 34/242 [14%]), and headache (17/242 [7%] vs 12/242 [5%]). INTERPRETATION: Once-daily dolutegravir is associated with a higher virological response rate than is once-daily ritonavir-boosted darunavir. Dolutegravir compares favourably in efficacy and safety to a boosted darunavir regimen with nucleoside reverse transcriptase inhibitor background treatment for HIV-1-infected treatment-naive patients. FUNDING: ViiV Healthcare and Shionogi & Co.

GdBaCo2O5+x layered perovskite as an intermediate temperature solid oxide fuel cell cathode

GdBaCo2O5+x (GBCO) was evaluated as a cathode for intermediate-temperature solid oxide fuel cells. A porous layer of GBCO was deposited on an anode-supported fuel cell consisting of a 15m thick electrolyte of yttria-stabilized zirconia (YSZ) prepared by dense screen-printing anda Ni–YSZ cermet as an anode (Ni–YSZ/YSZ/GBCO). Values of power density of 150 mW cm−2 at 700◦C and ca. 250 mW cm−2 at 800◦C are reported for this standard configuration using 5% of H2 in nitrogen as fuel. An intermediate porous layer of YSZ was introduced between the electrolyte and the cathode improving the performance of the cell. Values for power density of 300 mW cm−2 at 700◦C and ca. 500 mW cm−2 at 800◦C in this configuration were achieved.

Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate.

OBJECTIVE: The objective of this study was to compare posttreatment seizure severity in a phase III clinical trial of eslicarbazepine acetate (ESL) as adjunctive treatment of refractory partial-onset seizures. METHODS: The Seizure Severity Questionnaire (SSQ) was administered at baseline and posttreatment. The SSQ total score (TS) and component scores (frequency and helpfulness of warning signs before seizures [BS]; severity and bothersomeness of ictal movement and altered consciousness during seizures [DS]; cognitive, emotional, and physical aspects of postictal recovery after seizures [AS]; and overall severity and bothersomeness [SB]) were calculated for the per-protocol population. Analysis of covariance, adjusted for baseline scores, estimated differences in posttreatment least square means between treatment arms. RESULTS: Out of 547 per-protocol patients, 441 had valid SSQ TS both at baseline and posttreatment. Mean posttreatment TS for ESL 1200mg/day was significantly lower than that for placebo (2.68 vs 3.20, p<0.001), exceeding the minimal clinically important difference (MCID: 0.48). Mean DS, AS, and SB were also significantly lower with ESL 1200mg/day; differences in AS and SB exceeded the MCIDs. The TS, DS, AS, and SB were lower for ESL 800mg/day than for placebo; only SB was significant (p=0.013). For both ESL arms combined versus placebo, mean scores differed significantly for TS (p=0.006), DS (p=0.031), and SB (p=0.001). CONCLUSIONS: Therapeutic ESL doses led to clinically meaningful, dose-dependent reductions in seizure severity, as measured by SSQ scores. CLASSIFICATION OF EVIDENCE: This study presents Class I evidence that adjunctive ESL (800 and 1200mg/day) led to clinically meaningful, dose-dependent seizure severity reductions, measured by the SSQ.

Characterizing the vulnerability of frequent emergency department users by applying a conceptual framework: a controlled, cross-sectional study.

BACKGROUND: Frequent emergency department (ED) users meet several of the criteria of vulnerability, but this needs to be further examined taking into consideration all vulnerability's different dimensions. This study aimed to characterize frequent ED users and to define risk factors of frequent ED use within a universal health care coverage system, applying a conceptual framework of vulnerability. METHODS: A controlled, cross-sectional study comparing frequent ED users to a control group of non-frequent users was conducted at the Lausanne University Hospital, Switzerland. Frequent users were defined as patients with five or more visits to the ED in the previous 12 months. The two groups were compared using validated scales for each one of the five dimensions of an innovative conceptual framework: socio-demographic characteristics; somatic, mental, and risk-behavior indicators; and use of health care services. Independent t-tests, Wilcoxon rank-sum tests, Pearson's Chi-squared test and Fisher's exact test were used for the comparison. To examine the -related to vulnerability- risk factors for being a frequent ED user, univariate and multivariate logistic regression models were used. RESULTS: We compared 226 frequent users and 173 controls. Frequent users had more vulnerabilities in all five dimensions of the conceptual framework. They were younger, and more often immigrants from low/middle-income countries or unemployed, had more somatic and psychiatric comorbidities, were more often tobacco users, and had more primary care physician (PCP) visits. The most significant frequent ED use risk factors were a history of more than three hospital admissions in the previous 12 months (adj OR:23.2, 95%CI = 9.1-59.2), the absence of a PCP (adj OR:8.4, 95%CI = 2.1-32.7), living less than 5 km from an ED (adj OR:4.4, 95%CI = 2.1-9.0), and household income lower than USD 2,800/month (adj OR:4.3, 95%CI = 2.0-9.2). CONCLUSIONS: Frequent ED users within a universal health coverage system form a highly vulnerable population, when taking into account all five dimensions of a conceptual framework of vulnerability. The predictive factors identified could be useful in the early detection of future frequent users, in order to address their specific needs and decrease vulnerability, a key priority for health care policy makers. Application of the conceptual framework in future research is warranted.